GRN-1201

GRN-1201 is a peptide vaccine (4 peptides) from BrightPath Biotherapeutics. A cancer vaccine made of four peptides, tested in HLA-A*02 patients with resected melanoma and with pembrolizumab in PD-L1-positive metastatic NSCLC. Its furthest stage is phase 2, for melanoma and non-small cell lung cancer. ClinicalTrials.gov registers it in 2 studies linked below. Phase 1 in melanoma completed; phase 2 with pembrolizumab in NSCLC terminated ('Recruitment rate too slow'). Not on the company's current pipeline page. Whether it works in people has not been established unless a trial below reports it.